Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.8
3.9
Journals
Biomedicines
Special Issues
Advances in Immunotherapy and Radiation Therapy for Cancer (2nd Edition)
share announcement

Advances in Immunotherapy and Radiation Therapy for Cancer (2nd Edition)

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: 31 March 2026 | Viewed by 1898

Special Issue Editors

Dr. Ivaylo B. Mihaylov

E-Mail Website
Guest Editor
Department of Radiation Oncology, Miller School of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA
Interests: radiotherapy; radiation therapy; cancer detection; radiation oncology
Special Issues, Collections and Topics in MDPI journals
Dr. Benjamin Spieler

E-Mail Website
Guest Editor
Department of Radiation Oncology, Miller School of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA
Interests: radiotherapy; radiation therapy; radiation oncology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The goal of this Special Issue is to publish innovative research related to immunotherapy combined with radiotherapy for cancer treatment. The inclusion of additional treatment modalities, such as chemotherapy, targeted therapy, hyperthermia, etc., is also of interest. The Special Issue is open to both clinical and preclinical studies and to different disease sites and cancer types. The clinical studies should also encompass a preclinical component in order to be considered. The clinical component of interest is the impact of therapeutics on meaningful endpoints, such as progression-free and overall survival. In the preclinical setting, improving the synergy of combination therapeutics through the optimization of sequencing, dosing, timing, and fractionation is of particular interest. Both mechanistic and phenomenological studies will be considered. Submissions may be related either to tumor control/response or to normal tissue side effects resulting from treatment. Predictive modeling intended to support clinical decision-making and pertinent to disease response or normal tissue complications is an additional area of interest.

Dr. Ivaylo B. Mihaylov
Dr. Benjamin Spieler
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • radiotherapy
  • immunotherapy
  • outcome
  • toxicity
  • normal tissue
  • abscopal
  • tumor
  • systemic
  • local
  • response

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

28 pages, 1014 KB  
Review
The Role of Immunotherapy and Radiation Therapy in the Treatment of Breast Cancer
by Drishti Panse, Kristin Hsieh, Danielle Arons, Juliana Runnels, Monica Wassel, Anuja Shah, Rima Patel, Amy Tiersten, Anthony D. Nehlsen, Deborah Marshall, Robert M. Samstein, Sheryl Green and Julie Bloom
Biomedicines 2025, 13(9), 2209; https://doi.org/10.3390/biomedicines13092209 - 9 Sep 2025
Viewed by 1233
Abstract
Breast cancer is the most commonly diagnosed non-cutaneous cancer and is the leading cause of cancer mortality in females worldwide. Breast cancer incidence has been increasing over the last few decades; simultaneously, novel therapeutic agents including immunotherapies and targeted therapies have become more [...] Read more.
Breast cancer is the most commonly diagnosed non-cutaneous cancer and is the leading cause of cancer mortality in females worldwide. Breast cancer incidence has been increasing over the last few decades; simultaneously, novel therapeutic agents including immunotherapies and targeted therapies have become more prominent in use. Radiation therapy continues to serve as a cornerstone to breast cancer treatment in both early-stage and locoregionally advanced disease. Given the improvement in systemic agents, there is increasing interest in investigating the potential synergistic effect of radiation therapy and immunotherapy. As new trials and studies emerge demonstrating the clinical benefits of immune checkpoint inhibitors (ICIs) in breast cancer, especially in PD-L1-positive triple-negative breast cancer (TNBC), it is crucial to investigate the safety and efficacy of combining immunotherapy with radiation treatment. This narrative review discusses the impact of radiation therapy on anti-tumor immunogenicity, and examines the role of immunotherapy and radiation therapy in early-stage, locally advanced, recurrent, and metastatic breast cancer. We conducted a targeted literature search between 2010 and 2024, and included phase II/III clinical trials, mechanistic studies, and ongoing trials that evaluated the combination of immunotherapy (IO) and radiation therapy (RT). We discuss ongoing clinical studies, side effects, and optimal timing of combined IO and RT to enhance therapeutic outcomes. Full article
(This article belongs to the Special Issue Advances in Immunotherapy and Radiation Therapy for Cancer (2nd Edition))
►▼ Show Figures

Figure 1

Other

Jump to: Review

8 pages, 721 KB  
Brief Report
Preclinical Tumor Growth Delay Is More Reliable from Imaging-Based Rather than Manual Caliper Volume Measurements
by Ifeanyichukwu Ogobuiro, Benjamin Spieler and Ivaylo B. Mihaylov
Biomedicines 2025, 13(10), 2503; https://doi.org/10.3390/biomedicines13102503 - 14 Oct 2025
Viewed by 357
Abstract
Background/Objectives: Tumor growth delay is frequently used in preclinical experiments evaluating oncologic interventions. While treatment response in humans is based on imaging criteria for obvious reasons, manual caliper measurement of subcutaneous tumors is standard in animal studies. In a murine tumor model treated [...] Read more.
Background/Objectives: Tumor growth delay is frequently used in preclinical experiments evaluating oncologic interventions. While treatment response in humans is based on imaging criteria for obvious reasons, manual caliper measurement of subcutaneous tumors is standard in animal studies. In a murine tumor model treated with immunotherapy (ImT) and radiotherapy (RT), the reliability of caliper measurements was tested by comparing normalized tumor growth delay (NTGD) rates derived from caliper- and image-based volumetrics. Methods: A 4T1 breast syngeneic murine model was used, in which thirty animals were inoculated in the right inguinal mammary fat pad and the right axilla. One RT fraction of 8 Gy was delivered to the right inguinal tumor on day 11 post-implant, and intraperitoneal ImT (PD-1 checkpoint inhibitor) injections were administered on days 11, 12, and 14. Each animal underwent three MRI scans (days 10, 17, and 20). Caliper measurements were also performed by two independent observers on the same days. The measurements were averaged and used to estimate ellipsoid tumor volumes. The acquired MRIs were used for image segmentation and volume estimation. Tumor volumes (days 17 and 20) were normalized against the baseline pre-treatment tumor volume (day 10). NTGD rates derived from hand- and image-based volumetrics were compared to assess the reliability of caliper vs. MRI estimation. Results: Caliper volumes between the two observers correlated at 0.799 (Pearson, p < 0.001). The averaged caliper volumes correlated with MRI volumes at 0.897 (Pearson, p < 0.001). Absolute volume differences between caliper and MRI increased with tumor growth. NTGD-derived rates showed no correlation, with only 15% of NTGD caliper rates falling within 10% of the MRI rates. Conclusions: NTGD rate based on caliper volumes is a suitable measure of treatment response in preclinical studies. In the experiment described herein, caliper-derived NTGD rates did not correlate with MRI ground truth. These findings suggest that more accurate tumor volumetrics, derived from stored and verifiable medical imaging sources, should be used in preclinical assessment of oncologic interventions instead of standard caliper estimates. Full article
(This article belongs to the Special Issue Advances in Immunotherapy and Radiation Therapy for Cancer (2nd Edition))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop